Heart Failure Clinical Trial
— BIO-AffectDXOfficial title:
BIO-AffectDX Clinical Study
Verified date | January 2022 |
Source | Biotronik, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The purpose of the BIO-AffectDX Study is to prospectively evaluate improvement from baseline in heart failure subjects with atrial fibrillation (AF) implanted with a two-lead CRT-DX system, with emphasis on a comparison of patient outcomes between AF subtypes.
Status | Terminated |
Enrollment | 13 |
Est. completion date | December 29, 2021 |
Est. primary completion date | December 29, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Standard CRT-D indication according to current guidelines - Patient has documented history of paroxysmal, persistent, or long-standing persistent atrial fibrillation - De novo implant or upgrade from a DX implantable cardioverter-defibrillator (ICD) system - Implant planned to occur within 30 days of consent - Patient is able to understand English or Spanish - Patient is able to understand the nature of the study and provide informed consent - Patient is willing and able to complete all routine study visits at the investigational site for up to 12 months of follow-up - Patient is willing to utilize BIOTRONIK Home Monitoring® via CardioMessenger - Patient age is greater than or equal to 18 years After consent has been signed, additional inclusion criteria must be fulfilled for study participation: - Baseline subject assessment is evaluated as New York Heart Association class II, III or ambulatory IV heart failure at study Enrollment Visit - Baseline subject assessment of six-minute walk test is completed at study Enrollment Visit and walk distance = 450 meters (1,476 feet) Exclusion Criteria: - Contraindication to CRT-D/CRT-DX - Patient has current or previous atrial pacing need - Patient is considered for a His Bundle Pacing system - Patient has current or previous pacemaker, non-DX ICD implant, or bi-ventricular pacing system prior to enrolling - Patient is currently planned for a pulmonary vein isolation catheter ablation procedure within 3 months of consent - Patient life expectancy is less than 1 year - Patient is expected to receive heart transplantation or ventricular assist device within 1 year after implant - Patient is expected to have a cardiac surgical procedure, such as coronary artery bypass graft or valve transcatheter replacement/repair or surgery, planned to occur within 6-months after implant (excludes atrioventricular node ablation procedures) - Patient is currently on dialysis, or is expected to receive dialysis within 1 year of implant - Patient is enrolled in any investigational cardiac device or drug trial that might significantly affect the studied outcomes - Any condition (e.g. severe arthritis, wheelchair bound, etc.) preventing the patient from performing the required six-minute walk test - Conditions that prohibit placement of any of the system leads - Patient reports pregnancy at the time of consent |
Country | Name | City | State |
---|---|---|---|
United States | University of Michigan | Ann Arbor | Michigan |
United States | Massachusetts General Hospital | Boston | Massachusetts |
United States | Medical University of South Carolina | Charleston | South Carolina |
United States | Erlanger Institute for Clinical Research | Chattanooga | Tennessee |
United States | University of Cincinnati | Cincinnati | Ohio |
United States | Heart Rhythm Associates | Greenville | North Carolina |
United States | Upstate Cardiology | Greenville | South Carolina |
United States | University of Iowa Hospitals and Clinics | Iowa City | Iowa |
United States | Glacier View Research Institute Cardiology | Kalispell | Montana |
United States | University of Kansas Medical Center | Kansas City | Kansas |
United States | University of California San Diego - La Jolla | La Jolla | California |
United States | Baptist Health Lexington | Lexington | Kentucky |
United States | University of Kentucky - Gill Heart and Vascular Institute | Lexington | Kentucky |
United States | Lenox Hill Hospital | New York | New York |
United States | Weill Cornell Medicine | New York | New York |
United States | Orlando Health Heart Institute | Orlando | Florida |
United States | Kansas City Heart Rhythm Institute | Overland Park | Kansas |
United States | Mercy Hospital Springfield | Springfield | Missouri |
United States | AdventHealth Tampa | Tampa | Florida |
United States | ProMedica Northwest Ohio Cardiology Consultants | Toledo | Ohio |
United States | Cardiology Associates of North Mississippi | Tupelo | Mississippi |
United States | Cardiology Associates Medical Group | Ventura | California |
United States | Michigan Heart | Ypsilanti | Michigan |
Lead Sponsor | Collaborator |
---|---|
Biotronik, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Clinical Composite Score from baseline | 12 months | ||
Secondary | Rate of composite all-cause death and heart failure | 12 months | ||
Secondary | Change in quality of life questionnaires from baseline for all patients and by atrial fibrillation sub-type | 6 and 12 months | ||
Secondary | Change in New York Heart Association class from baseline for all patients and by atrial fibrillation sub-type | 6 and 12 months | ||
Secondary | Change in six-minute walk distance from baseline for all patients and by atrial fibrillation sub-type | 6 and 12 months | ||
Secondary | Change in atrial fibrillation burden from baseline for all patients and by atrial fibrillation sub-type | 6 and 12 months | ||
Secondary | Change in Clinical Composite Score from baseline | 6 months | ||
Secondary | Rate of major complications | 12 months | ||
Secondary | Rate of conversion to sinus rhythm | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Recruiting |
NCT05196659 -
Collaborative Quality Improvement (C-QIP) Study
|
N/A | |
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Active, not recruiting |
NCT05896904 -
Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction
|
N/A | |
Completed |
NCT05077293 -
Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
|
||
Recruiting |
NCT05631275 -
The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
|
||
Enrolling by invitation |
NCT05564572 -
Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology
|
N/A | |
Enrolling by invitation |
NCT05009706 -
Self-care in Older Frail Persons With Heart Failure Intervention
|
N/A | |
Recruiting |
NCT04177199 -
What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
|
||
Terminated |
NCT03615469 -
Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY)
|
N/A | |
Recruiting |
NCT06340048 -
Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure
|
Phase 1/Phase 2 | |
Recruiting |
NCT05679713 -
Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
|
||
Completed |
NCT04254328 -
The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure
|
N/A | |
Completed |
NCT03549169 -
Decision Making for the Management the Symptoms in Adults of Heart Failure
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Enrolling by invitation |
NCT05538611 -
Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
|
||
Recruiting |
NCT04262830 -
Cancer Therapy Effects on the Heart
|
||
Completed |
NCT06026683 -
Conduction System Stimulation to Avoid Left Ventricle Dysfunction
|
N/A | |
Withdrawn |
NCT03091998 -
Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support
|
Phase 1 | |
Recruiting |
NCT05564689 -
Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy
|